| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81d6af637871c95f327e1ea7d2593047 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate |
2006-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4825eadd4a62cdcab8236648d219518
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e15399220ee04bdbc470f058710f324
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b94bc912329c226f35666efafcf8ecf1 |
| publicationDate |
2008-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1967527-A1 |
| titleOfInvention |
A g protein-coupled receptor antagonist and its use for preventing and treating alzheimer s disease |
| abstract |
The invention discloses methods for screening a reagent for treating or preventing Alzheimer's disease or related neurological pathology. A method according to the invention includes the steps of: (a) activating a receptor and determining a first extent of endocytosis of the receptor, wherein the receptor is a G-protein coupled receptor that associates with presenilin-1; (b) activating the receptor under the same conditions as in step (a), in the presence of a candidate reagent, and determining a second extent of endocytosis of the receptor; (c) determining a difference between the first extent of endocytosis and the second extent of endocytosis; and (d) repeating steps (a) - (c), if the difference is less than a threshold. The invention also disclose uses of receptor antagonists for manufacturing medicaments for treating or preventing Alzheimer's disease or related neurological pathology, wherein the receptor antagonists inhibit endocytosis of a G-protein coupled receptor that associates with presenilin-1 during endocytosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2005174-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7851228-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9512191-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010132609-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10774121-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8945858-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2005174-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8129334-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8389478-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8951794-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10221223-B2 |
| priorityDate |
2005-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |